Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.
FDA Puts Clinical Hold On Novavax COVID-19-Influenza Combo Vaccine Candidate; Stock Tumbles
Wednesday said the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its COVID-19-Influenza
Novavax stock plunges as FDA puts clinical hold on COVID-flu combo vaccine
Novavax shares plummet 30% as FDA places clinical hold on COVID-19 and influenza combination vaccine due to serious adverse event.
Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates
Novavax Inc.’s stock tumbled 19% early Wednesday after the company said the Food and Drug Administration has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates,
Novavax Stock Plummets as FDA Pauses Clinical Trial on Safety Concerns
Novavax stock fell sharply Wednesday after the U.S. Food and Drug Administration halted one of the vaccine maker’s clinical trials, citing safety concerns.Shares plummeted 18% to $10.32 in midday trading.
Novavax Stock Plunges as FDA Puts Hold on Vaccines Because of Safety Concerns
Key Takeaways The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns.The moves came as one patient who took the combination shot reported nerve damage.
Novavax reports FDA placed clinical hold on IND for COVID-flu combo vaccine
Novavax announced that the U.S. Food and Drug Administration has placed a clinical hold on Novavax’s Investigational New Drug, or IND, application for its COVID-19-Influenza Combination, or CIC, and stand-alone influenza vaccine candidates.
Novavax Plunges After FDA Hold on Flu, Covid Vaccine Work
Novavax Inc. shares fell as much as 24% after US regulators placed a hold on the company’s experimental influenza and Covid-19 combination vaccines because a study volunteer developed a serious nerve disorder.
bovnews5h
NVAX Unveiled: The Shocking Truth Behind Novavax Inc’s Latest Stock Movements
On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...
Zacks.com on MSN12m
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.
Novavax’s Regulatory Setback and Mid-Term Underperformance: An Analyst’s Perspective
Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.
Hosted on MSN19h
Novavax (NASDAQ:NVAX) Stock Drops 18% after Clinical Trial Is Halted
Shares of pharmaceutical company Novavax ($NVAX) are down 18% on news that the U.S. Food and Drug Administration (FDA) has ...
news.stocktradersdaily7h
Trading (NVAX) With Integrated Risk Controls
Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.
kalkinemedia9h
Novavax, Inc. (NASDAQ:NVAX) Shares Tumbled on Wednesday Following Clinical Hold on Flu Combination Vaccine
Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years ...
SchaeffersResearch.com22h
3 Vaccine Stocks to Watch as Flu Season Approaches
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...
bovnews2d
Why Did Novavax Inc (NVAX) Stock See -17.13% Plunge in the Last 90 Days?
On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.53 which represents a decrease of $-0.37 or -2.87% from the prior close of $12.9. The stock opened at $12.72 and touched a low ...
Business Insider1d
Cautious Optimism for Novavax Amid Clinical Hold Challenges
Jefferies analyst Roger Song has maintained their bullish stance on NVAX stock, giving a Buy rating on October 10. Roger Song has given his Buy rating due to a combination of factors that, despite ...